Nuclear IRF-1 expression as a mechanism to assess “Capability” to express PD-L1 and response to PD-1 therapy in metastatic melanoma

Nuclear IRF-1 expression as a mechanism to assess “Capability” to express PD-L1 and response to PD-1 therapy in metastatic melanoma

Background Predictive biomarkers for antibodies against programmed death 1 (PD-1) remain a major unmet need in metastatic melanoma. Specifically, response is seen in tumors that do not express programmed death ligand 1 (PD-L1), highlighting the need for a more sensitive biomarker. We hypothesize tha...

Full description

Saved in:
Bibliographic Details
Main Authors: Mario Sznol, Harriet M. Kluger, Pok Fai Wong, James W. Smithy, David L. Rimm, Vasiliki Pelekanou, Lauren M. Moore, Jamaal Rehman, Patricia Gaule, Veronique M. Neumeister
Format: Article
Language:English
Published: BMJ Publishing Group 2017-12-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/5/1/25.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items